MX2019014475A - Formulaciones de lixivaptan para el tratamiento de enfermedades poliquisticas. - Google Patents

Formulaciones de lixivaptan para el tratamiento de enfermedades poliquisticas.

Info

Publication number
MX2019014475A
MX2019014475A MX2019014475A MX2019014475A MX2019014475A MX 2019014475 A MX2019014475 A MX 2019014475A MX 2019014475 A MX2019014475 A MX 2019014475A MX 2019014475 A MX2019014475 A MX 2019014475A MX 2019014475 A MX2019014475 A MX 2019014475A
Authority
MX
Mexico
Prior art keywords
lixivaptan
formulations
treatment
polycystic disease
polycystic
Prior art date
Application number
MX2019014475A
Other languages
English (en)
Inventor
Lorenzo Pellegrini
Original Assignee
Palladio Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palladio Biosciences Inc filed Critical Palladio Biosciences Inc
Publication of MX2019014475A publication Critical patent/MX2019014475A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients

Abstract

Se proporcionan formulaciones de lixivaptan, y métodos para usar el mismo, para el tratamiento de la enfermedad poliquística.
MX2019014475A 2017-06-09 2018-06-08 Formulaciones de lixivaptan para el tratamiento de enfermedades poliquisticas. MX2019014475A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762517793P 2017-06-09 2017-06-09
US201762580167P 2017-11-01 2017-11-01
PCT/US2018/036719 WO2018227128A1 (en) 2017-06-09 2018-06-08 Formulations of lixivaptan for the treatment of polycystic disease

Publications (1)

Publication Number Publication Date
MX2019014475A true MX2019014475A (es) 2020-08-17

Family

ID=64566299

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014475A MX2019014475A (es) 2017-06-09 2018-06-08 Formulaciones de lixivaptan para el tratamiento de enfermedades poliquisticas.

Country Status (8)

Country Link
US (2) US11241441B2 (es)
EP (1) EP3634395A4 (es)
JP (1) JP2020523305A (es)
KR (1) KR20200027470A (es)
AU (1) AU2018279843A1 (es)
CA (1) CA3065910A1 (es)
MX (1) MX2019014475A (es)
WO (1) WO2018227128A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11241441B2 (en) * 2017-06-09 2022-02-08 Palladio Biosciences, Inc. Formulations of lixivaptan for the treatment of polycystic disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516774A (en) * 1993-07-29 1996-05-14 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
US5972882A (en) * 1997-12-15 1999-10-26 University Of Kansas Medical Center Treatment of polycystic kidney disease using vasopressin V2 receptor antagonists
US6352718B1 (en) * 1999-09-27 2002-03-05 American Cyanamid Company Vasopressin antagonist formulation and process
US20080221084A1 (en) * 2006-10-30 2008-09-11 Otsuka Pharmaceutical Co., Ltd. Method for reducing infarction using vasopressin antagonist compounds, and compositions and combinations therefor
WO2011025771A1 (en) 2009-08-25 2011-03-03 Biogen Idec Ma Inc. Compositions for delivery of insoluble agents
CA2888462A1 (en) 2012-10-19 2014-04-14 Synta Pharmaceuticals Corp. Treating polycystic kidney disease with hsp90 inhibitory compounds
WO2016077370A1 (en) * 2014-11-10 2016-05-19 Ferrara Giovanni Antonio Novel methods for treatment and prophylaxis of polycystic kidney disease
US11241441B2 (en) * 2017-06-09 2022-02-08 Palladio Biosciences, Inc. Formulations of lixivaptan for the treatment of polycystic disease

Also Published As

Publication number Publication date
EP3634395A4 (en) 2021-03-10
JP2020523305A (ja) 2020-08-06
AU2018279843A1 (en) 2019-12-19
WO2018227128A1 (en) 2018-12-13
CA3065910A1 (en) 2018-12-13
US20200147102A1 (en) 2020-05-14
US20220110944A1 (en) 2022-04-14
EP3634395A1 (en) 2020-04-15
KR20200027470A (ko) 2020-03-12
US11241441B2 (en) 2022-02-08

Similar Documents

Publication Publication Date Title
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
MX2019007021A (es) Anticuerpos il-11ra.
MX2019007020A (es) Anticuerpos il-11.
WO2017124002A8 (en) Multispecific immunomodulatory antigen-binding constructs
MY191581A (en) Anti-pd-1 antibodies
GB2541571A (en) Pharmaceutical compositions
SG10201803042PA (en) Anti-tim-3 antibodies
EP3675859A4 (en) COMPOUNDS, COMPOSITIONS AND PROCEDURES FOR TREATMENT OF DISEASES
EP3800248A3 (en) Crispr-cas-related methods, compositions and components for cancer immunotherapy
NZ731789A (en) Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
SG10201809668TA (en) Anti-her2 antibodies and immunoconjugates
MY192927A (en) Fused bicyclic compounds for the treatment of disease
SG10201809628SA (en) Anti-ptk7 antibody-drug conjugates
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX369623B (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
PH12018502154A1 (en) Methods of treating ocular conditions
MX2018000395A (es) Proteinas y composiciones inmunizantes que contienen proteinas de klebsiella y metodos de uso.
NZ742805A (en) Anti-cd22 antibody-maytansine conjugates and methods of use thereof
PH12017500602A1 (en) Methods for treating ocular conditions
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
EP4285930A3 (en) Protein formulations
MX370897B (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades,.
JOP20190164B1 (ar) تركيبات وطرق لعلاج داء فاربر
WO2017161344A8 (en) Compositions and methods for treating parasitic diseases
MX2018014034A (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades.